Roth Capital Resumes BioLineRx (BLRX) at Buy
Tweet
Share
E-mailGet Alerts BLRX Hot Sheet
Price: $2.85 -2.4%
Rating Summary:
6 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 14 | New: 29
Rating Summary:
6 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 14 | New: 29
Join SI Premium – FREE
Roth Capital resumed coverage on BioLineRx (NASDAQ: BLRX) with a Buy rating and a price target of $8.00.
For an analyst ratings summary and ratings history on BioLineRx click here. For more ratings news on BioLineRx click here.
Shares of BioLineRx closed at $2.06 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026
- Guggenheim Starts AppFolio (APPF) at Buy
- Lucid Capital Markets Starts Industrial Logistics Properties Trust (ILPT) at Buy
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
